Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Institute of Oncology Prof. Dr. Ion Chiricuta · Central European Cooperative Oncology Group · +15 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
1,117
total citations
- FWCI
- 99.66
- Percentile
- 100%
- References
- 45
Citations per year
Authors
19- TCTudor–Eliade Ciuleanu
Institute of Oncology Prof. Dr. Ion Chiricuta, Central European Cooperative Oncology Group
- TBThomas Brodowicz
Central European Cooperative Oncology Group, Vienna General Hospital
- CZChristoph Zielinski
Central European Cooperative Oncology Group, Vienna General Hospital
- JHJoo Hang Kim
Yonsei University
- MKMaciej Krzakowski
Central European Cooperative Oncology Group, The Maria Sklodowska-Curie National Research Institute of Oncology
Topics & keywords
Topics
Keywords
- Pemetrexed
- Medicine
- Tolerability
- Internal medicine
- Placebo
- Clinical endpoint
- Hazard ratio
- Lung cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.